Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Andalas Energy And Power Plc LSE:ADL London Ordinary Share IM00BZ7PNY71 ORD NPV
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.015p +10.00% 0.165p 0.15p 0.18p 0.165p 0.15p 0.15p 6,000,000 09:52:34
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Alternative Energy 0.0 -1.0 -0.0 - 1.00

Andalas Energy And Power Share Discussion Threads

Showing 4551 to 4571 of 5100 messages
Chat Pages: Latest  192  191  190  189  188  187  186  185  184  183  182  181  Older
DateSubjectAuthorDiscuss
29/6/2018
09:08
Yes. Back up to the 30s soon enough.
domple
28/6/2018
18:12
* The Company expects to announce and publish its audited accounts for the year ended 30 April 2018 (the "Accounts") in June 2018; Will we see them tomorrow or will this be the first of many broken promises from the new Messiah Gorringe?
sweet karolina
28/6/2018
12:51
ADL -mm's taking plenty...i think a big buy order is being filled here folks.
pre
28/6/2018
12:46
Chaps Farn just moved 10%. delayed reaction. Faron Pharmaceuticals Oy Clevegen successful toxicity studies 28/06/2018 7:01am RNS Non-Regulatory TIDMFARN Faron Pharmaceuticals Oy 28 June 2018 Faron Pharmaceuticals Ltd ("Faron" or the "Company") Clevegen shows good safety and potential to block Clever-1 on circulating monocytes -- Wholly-owned Clevegen (FP-1305) shows no toxicity in dose escalation studies in large preclinical models -- The no-observed-adverse-effect-level (NOAEL) was 100 mg/kg, which is roughly 30 times higher concentration than needed for Clever-1 occupancy in vivo -- Clevegen also blocked Clever-1 on circulating monocytes as expected. The duration of blocking was dose dependent and resumed to normal level in 20 days in the highest dose -- The Company expects CTA filing for MATINS study in Q3 2018 and first patient recruitment in Q4 2018 TURKU - FINLAND, 28 June 2018 - Faron Pharmaceuticals Ltd ("Faron") (AIM: FARN), the clinical stage biopharmaceutical company, today announces successful toxicity studies and control of blood Clever-1 positive monocytes, precursor cells to tumour associated macrophages (TAM) in large preclinical models. The toxicity studies were designed to fulfil regulatory requirements for 3-week interval intravenous administration of Clevegen, typical for other anti-cancer antibodies currently in use. FP-1305 is a humanized IgG4 monoclonal antibody produced in CHO -cells by Faron collaborator Abzena. The FP-1305 drug product in its final formulation was administered as a single dose at 3, 30 and 100 mg/kg. No toxicologically relevant changes were observed in any subject. No major changes were observed after treatment with FP-1305 in T lymphocytes subsets. The binding of Clevegen to its receptor on circulating CD14+ monocytes was confirmed by investigating the receptor occupancy, the recovery of which occurred between 3 to 20 days after dosing in a dose-dependent manner. No relevant changes were present in cytokines and no anti-drug antibodies (ADA) were detected in any subject. Therefore, the highest dose of 100 mg/kg was considered the no-observed-adverse-effect-level (NOAEL).
1lilac
28/6/2018
12:38
0.0234 to buy at present so many buys showing as sells
maytrees
28/6/2018
08:34
It'll be a complete lockout, you won't be able to buy unless you are in before the news lands.
jace86
27/6/2018
16:57
Going to be some hefty gains in next week. Mark my words
ernestsyngen
27/6/2018
00:04
Can't believe theyve dragged in mugs to keep buying this con.
tidy 2
26/6/2018
18:12
Ron.. Im going for 5-0 England :-)
therealtonythetiger
26/6/2018
16:47
Now is the time to get stuck into the bookies the top team And the 2nd Top want to quality so both teams want a point so 00 11 is the game play
ronjoe77
26/6/2018
16:44
HTTPS://www.voxmarkets.co.uk/blogs/eco-atlantic-oil-gas-eco-alan-green-pfc-adl-sdy-apollo-minerals/
timw3
26/6/2018
16:34
nice podcast...thanks Tiger looks like the company has turned the corner and is looking at some very exciting near term projects...saw that 90m buy @0.30 earlier..hummm
pre
26/6/2018
16:24
Nice to see you're back Ron. Looking forward to some more peachy posts.
domple
26/6/2018
16:20
hxxps://www.voxmarkets.co.uk/blogs/eco-atlantic-oil-gas-eco-alan-green-pfc-adl-sdy-apollo-minerals/
therealtonythetiger
26/6/2018
16:20
Hows your luck Ron..
therealtonythetiger
26/6/2018
16:08
It's been done And dusted a longtime ago get in it's "00
ronjoe77
26/6/2018
15:54
How to turn 1k into 1/2 mill ok back draw on this game France v Denmark
ronjoe77
26/6/2018
15:43
If you're here to make money, we'll the World Cup just got so good for youFrance v Denmark will be 00 And a point each just check out rest that are in same situ now is the time to back 00 11 or lay under goals
ronjoe77
26/6/2018
14:53
please stick to ADL topics
domple
26/6/2018
14:41
Get in about to double AorTech International PLC New Patent Issued 26/06/2018 12:49pm UK Regulatory (RNS & others) Aortech (LSE:AOR) Intraday Stock Chart Today : Tuesday 26 June 2018 Click Here for more Aortech Charts. TIDMAOR RNS Number : 6329S AorTech International PLC 26 June 2018 26 June 2018 AorTech International plc ("AorTech" or the "Company") New Patent Issued AorTech is pleased to announce that the US Patent Office has recently granted Patent Number 9,994,668 entitled "BIOSTABLE POLYURETHANES". The invention relates to polyurethanes and processes for their preparation. The polyurethanes are biostable, creep resistant, acid resistant and abrasion resistant which makes them useful in the manufacture of biomaterials and medical devices, articles or implants, in particular, long term implantable medical devices in the fields of cardiology, orthopaedics, plastic surgery and gastroenterology. Bill Brown, Chairman of AorTech said: "We are delighted that this US Patent has been issued extending further AorTech's world class portfolio of biostable polymers for medical device use." For further information contact: AorTech International plc Tel: +44 (0)7730 718296 Bill Brown, Chairman Stockdale Securities Limited Tel: +44 20 7601 6100 Tom Griffiths/David Coaten About AorTech:
1lilac
26/6/2018
14:29
Euclid I would prefer a primary bid raise than a cln at least pi's can take part
hope67
Chat Pages: Latest  192  191  190  189  188  187  186  185  184  183  182  181  Older
Your Recent History
LSE
ADL
Andalas En..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190627 11:08:36